B+
Bull case
30%
Probability
Target price
$9.00
+16.1% vs current
PAYS
PaysignBNasdaq / Financial Services
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
45%
Probability
Target price
$7.00
-9.7% vs current
B-
Bear case
25%
Probability
Target price
$4.50
-41.9% vs current
AI sentiment snapshot
Latest data as of 2026-05-15
Recent news sentiment (30D)
+18.4
Positive
Company
+23.6
Positive
Macro
+18.6
Positive
Pulse
-32.0
Negative
Sentiment proxy
+42.9
Score
AI commentary
This is still a cautious monitoring-style post-earnings memo rather than a full risk-on upgrade. Primary-source support is good because the view is anchored by the May 12, 2026 earnings release and the May 13, 2026 10-Q, but post-print tape action was mixed: trusted market coverage said the stock fell as much as 27.7% intraday on May 13 before finishing down 12.3% because investors wanted a guidance raise, and the May 14 anchor close was $5.79. Analyst follow-through appears thin so far, with only limited visible revision support, and there is no social-context coverage in the packet to offset that caution.
RankAlpha Sentiment Codex - 2026-05-15
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-06-30catalystQ2 exit targets are now the clearest near-term proof point after the Q1 beatHigh impact
Paysign's May 12, 2026 earnings release said first-quarter revenue, operating margin, and net income all finished above the high end of prior ranges, while management reiterated full-year guidance and expects to exit the second quarter with 147-150 active patient affordability programs and 555-560 plasma centers. That gives investors a dated operating checkpoint after the market sold off on unchanged full-year guidance [#8-K-2026-05-12].
2026-12-31eventNew $5 million repurchase authorization adds modest capital-allocation supportMedium impact
The 10-Q disclosed that on May 8, 2026 the board authorized a new stock repurchase program for up to $5 million over 36 months expiring May 7, 2029, after the prior authorization expired in March. The authorization is not the core thesis, but it can support sentiment if cash generation remains healthy and management buys into weakness [#10-Q-2026-05-13].
2026-12-31catalystPatient-affordability mix is still the main earnings engineHigh impact
The earnings release showed Q1 2026 pharma revenue up 81.9% to $15.68 million, patient affordability at 135 active programs, gross margin up to 65.0%, and operating margin up to 23.8%, while the 10-Q showed pharma growth was driven by new patient-affordability launches and plasma growth was helped by normalized donation trends. If that mix persists, Paysign still has a credible path to the upper half of its full-year framework [#8-K-2026-05-12] [#10-Q-2026-05-13].
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-15 • Updated nightlySource: Internal modelMethodology